Comparative Effectiveness Study Proposals Requested By AHRQ
This article was originally published in The Pink Sheet Daily
Executive Summary
AHRQ is asking CERTs for proposals to conduct short-term research programs examining existing data on the 10 priority areas the agency has identified. The research is part of AHRQ’s mandate under the Medicare Modernization Act.
You may also be interested in...
AHRQ Singles Out “Priority Conditions” For Comparing Drug Effectiveness
The Agency for Healthcare Research & Quality will conduct comparative research on drugs used for 10 of the top conditions affecting Medicare beneficiaries, including ischemic heart disease, asthma and stroke. AHRQ will use the $15 mil. provided in the fiscal year 2005 omnibus appropriations bill.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.